

NCT ID	NCT03940820
Title	Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors
Phase	Phase 1/Phase 2
Date Added	2019-05-07
Location	China
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	ROBO1 CAR-NK cells
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03795311
Title	Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)
Phase	Phase 1, Phase 2
Date Added	2019-01-07
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	FOLFIRINOX Bevacizumab
Tags	MSS/ MMRp
NCT ID	NCT03874897
Title	Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Phase	Phase 1
Date Added	2019-03-14
Location	China
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	CAR-CLDN18.2 T-Cells, Chemotherapy, PD-1 Monoclonal Antibody
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04046445
Title	Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Phase	Phase 1
Date Added	2019-08-06
Location	Arizona, United States California, United States Colorado, United States New York, United States North Carolina, United States Texas, United States Belgium Germany Switzerland
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	ATP128, BI 754091, VSV-GP128
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT03867799
Title	iSCORE: Immunotherapy Sequencing in COLon and REctal Cancer
Phase	Phase 2
Date Added	2019-03-08
Location	United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nivolumab
Tags	MSS/ MMRp

NCT ID	NCT02499328
Title	Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Phase	Phase 1, Phase 2
Date Added	2015-07-16
Location	Alabama, United States California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States Belgium Germany Italy Spain United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	AZD5069, AZD9150, MEDI4736, tremelimumab (treme)
Tags	MSS/ MMRp

NCT ID	NCT04017650
Title	Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2019-07-12
Location	Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, encorafenib, Nivolumab
Tags	MSS/ MMRp

NCT ID	NCT03711058
Title	Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Phase	Phase 1, Phase 2
Date Added	2018-10-18
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Copanlisib, Nivolumab
Tags	MSS/ MMRp
NCT ID	NCT05167409
Title	A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2021-12-22
Location	Arizona, United States Colorado, United States New Jersey, United States Virginia, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	ALX148, cetuximab, Evorpacept (ALX148), Pembrolizumab, Erbitux, Keytruda
Tags	MSS/ MMRp
NCT ID	NCT03727763
Title	Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Phase	Phase 2
Date Added	2018-11-01
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	cetuximab, Vemurafenib
Tags	MSI-H/ MMRd, MSS/ MMRp